CY1109962T1 - Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας - Google Patents

Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας

Info

Publication number
CY1109962T1
CY1109962T1 CY20101100325T CY101100325T CY1109962T1 CY 1109962 T1 CY1109962 T1 CY 1109962T1 CY 20101100325 T CY20101100325 T CY 20101100325T CY 101100325 T CY101100325 T CY 101100325T CY 1109962 T1 CY1109962 T1 CY 1109962T1
Authority
CY
Cyprus
Prior art keywords
compounds
triazaspiro
decan
substituted
obesity treatment
Prior art date
Application number
CY20101100325T
Other languages
English (en)
Inventor
Corinna Sundermann
Bernd Sundermann
Stefan Oberbörsch
Werner Englberger
Hagen-Heinrich Hennies
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1109962T1 publication Critical patent/CY1109962T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

Η παρούσα εφεύρεση αφορά υποκατεστημένες ενώσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-όνης του τύπου I, μεθόδους για την παρασκευή τους, φάρμακα που περιέχουν την ένωση αυτή καθώς και τη χρησιμοποίηση των ενώσεων αυτών για την παρασκευή φαρμάκων.
CY20101100325T 2004-03-22 2010-04-09 Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας CY1109962T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004014296A DE102004014296A1 (de) 2004-03-22 2004-03-22 Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen
EP05716285A EP1730147B1 (de) 2004-03-22 2005-03-22 Substituierte 1,4,8-triazaspiro[4.5 decan-2-on-verbindungen zur behandlung von fettsucht

Publications (1)

Publication Number Publication Date
CY1109962T1 true CY1109962T1 (el) 2014-09-10

Family

ID=34961883

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100325T CY1109962T1 (el) 2004-03-22 2010-04-09 Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας

Country Status (13)

Country Link
US (1) US7951815B2 (el)
EP (1) EP1730147B1 (el)
JP (1) JP2007529565A (el)
AT (1) ATE457027T1 (el)
CA (1) CA2560293C (el)
CY (1) CY1109962T1 (el)
DE (2) DE102004014296A1 (el)
DK (1) DK1730147T3 (el)
ES (1) ES2340502T3 (el)
PL (1) PL1730147T3 (el)
PT (1) PT1730147E (el)
SI (1) SI1730147T1 (el)
WO (1) WO2005095402A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
US8653068B2 (en) * 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US9340558B2 (en) 2007-11-02 2016-05-17 Pain Therapeutics Inc. Filamin a binding anti-inflammatory and analgesic
WO2010051497A1 (en) * 2008-10-31 2010-05-06 Pain Therapeutics, Inc. Filamin a binding anti-inflammatory and analgesic
AU2009308769B2 (en) * 2008-10-31 2015-03-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
US8580808B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutic, Inc. Filamin A-binding anti-inflammatory analgesic
US8580809B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
WO2014012054A1 (en) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patent
DK2882428T3 (en) 2012-07-13 2019-04-15 Pain Therapeutics Inc PROCEDURE TO INHIBIT TAU PHOSPHORIZATION
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048830A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048831A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
AR116020A1 (es) 2018-09-03 2021-03-25 Bayer Ag COMPUESTOS DE 3,9-DIAZAESPIRO[5.5]UNDECANO COMO INHIBIDORES DE GGTasa I Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725389A (en) * 1971-07-02 1973-04-03 American Home Prod Adducts of delta-aminobenzylpenicillin and n-substituted-4-piperidones
JP2575446B2 (ja) * 1988-02-12 1997-01-22 武田薬品工業株式会社 トリアザスピロ化合物
SI0921125T1 (en) * 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
ES2194402T3 (es) * 1998-06-12 2003-11-16 Hoffmann La Roche Derivados de di - o triaza-espiro(4,5)decano..
AU1682400A (en) * 1998-12-09 2000-06-26 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds
WO2001096337A1 (fr) * 2000-06-14 2001-12-20 Banyu Pharmaceutical Co.,Ltd Composes heterocycliques 4-oxoimidazolidine-2-spiro-azotes
DE60226874D1 (de) * 2001-07-23 2008-07-10 Banyu Pharma Co Ltd 4-oxoimidazolidin-2-spiro piperidin derivat

Also Published As

Publication number Publication date
US20070015784A1 (en) 2007-01-18
WO2005095402A1 (de) 2005-10-13
WO2005095402A9 (de) 2009-06-11
SI1730147T1 (sl) 2010-05-31
DE502005008971D1 (de) 2010-03-25
CA2560293A1 (en) 2005-10-13
DE102004014296A1 (de) 2005-10-06
EP1730147B1 (de) 2010-02-03
ES2340502T3 (es) 2010-06-04
ATE457027T1 (de) 2010-02-15
PL1730147T3 (pl) 2010-07-30
JP2007529565A (ja) 2007-10-25
PT1730147E (pt) 2010-04-16
CA2560293C (en) 2013-01-22
EP1730147A1 (de) 2006-12-13
US7951815B2 (en) 2011-05-31
DK1730147T3 (da) 2010-05-31

Similar Documents

Publication Publication Date Title
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
SE0301700D0 (sv) Novel compounds
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
TW200626553A (en) Novel compounds
NO20055219L (no) Nye forbindelser
NO20055977L (no) Nye benzimidazolderivater
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
TW200745122A (en) New compounds I
SE0302546D0 (sv) New compounds
DE602004031410D1 (de) Inden derivate als pharmazeutika
DK1869038T3 (da) Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler
NO20063619L (no) Diarylmetylpiperazinderivater, fremstilling og anvendelse derav
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
SE0401763D0 (sv) Compounds
TW200745133A (en) New compounds II
SE0303280D0 (sv) Novel compounds
NO20055997L (no) Diarylmetylidenpiperidinderivater og deres anvendelse som opiodreseptoragonister
SE0403118D0 (sv) New compounds 2
SE0403117D0 (sv) New compounds 1
NO20063617L (no) Diarylmetylidenpiperidinderivater, fremstilling og anvendelse derav
NO20063618L (no) Diarylmetylpiperidinderivater, fremstilling og anvendelse derav
SE0401716D0 (sv) New compounds